PACB Quote, Financials, Valuation and Earnings

Bruker Corp. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -6.8%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Bruker Corp.'s return on equity of -1.2%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.42, signalling upside risk potential of 2.84%. On the other hand Bruker Corp. has an analysts' consensus of $53.14 which suggests that it could grow by 7.45%. Given that Bruker Corp. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Bruker Corp. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.200, which suggesting that the stock is 120.046% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.854%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.4% to investors and pays a quarterly dividend of $0.05 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Pacific Biosciences of California, Inc.'s net income of -$38M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.58x versus 2.18x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of 14.91%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Boston Scientific Corp.'s return on equity of 12.46%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.42, signalling upside risk potential of 2.84%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.19 which suggests that it could grow by 39.05%. Given that Boston Scientific Corp. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Boston Scientific Corp. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.200, which suggesting that the stock is 120.046% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 48.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.58x versus 6.95x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -735.19%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.42, signalling upside risk potential of 2.84%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.27 which suggests that it could grow by 87.64%. Given that Intellia Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.200, which suggesting that the stock is 120.046% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.054, suggesting its more volatile than the S&P 500 by 105.378%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Pacific Biosciences of California, Inc.'s net income of -$38M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.58x versus 21.63x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -27.41%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.42, signalling upside risk potential of 2.84%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $39.00 which suggests that it could fall by -5.5%. Given that Pacific Biosciences of California, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Pacific Biosciences of California, Inc. is more attractive than Twist Bioscience Corp..

Pacific Biosciences of California, Inc. has a beta of 2.200, which suggesting that the stock is 120.046% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.191, suggesting its more volatile than the S&P 500 by 119.099%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 4.58x versus 6.59x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.